Experimental models of multiple sclerosis

Current Opinion in Neurology

Volumn 24, Issue 3, 2011, Pages 291-299

  Pachner, Andrew R ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

animal models; autoimmunity; demyelination; multiple sclerosis; virus

Indexed keywords

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; AUTOIMMUNE DISEASE; AXONAL INJURY; CENTRAL NERVOUS SYSTEM; DEMYELINATION; DISABILITY; DISEASE COURSE; ENCEPHALITIS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MULTIPLE SCLEROSIS; MURINE HEPATITIS CORONAVIRUS; MYELOOPTIC NEUROPATHY; NONHUMAN; PATHOGENESIS; STROKE;

ANIMALS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; VIRUS DISEASES;

EID: 79955626592     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328346c226     Document Type: Article

References (61)

1. Rodriguez M. Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis. Brain Pathol 2007; 17:219-229. (Pubitemid 46466141)
2. Blakemore WF, Franklin RJ. Remyelination in experimental models of toxininduced demyelination. Curr Top Microbiol Immunol 2008; 318:193-212.
3. Hemachudha T, Phanuphak P, Johnson RT, et al. Neurologic complications of Semple-type rabies vaccine: clinical and immunologic studies. Neurology 1987; 37:550-556. (Pubitemid 17057927)
4. Koritschoner RS, Schweinburg F. Induktion von Paralyse und Ruckenmarksentzundung durch Immunisierung von Kaninchen mit menschlichem Ruckenmarksgewebe. Z Immunitatsf Exp Ther 1925; 42:217-283.
5. Rivers TM, Spunt DH, Berry GP. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med 1933; 58:39-53.
6. Waksman BH, Porter H, Lees MD, et al. A study of the chemical nature of components of bovine white matter effective in producing allergic encephalomyelitis in the rabbit. J Exp Med 1954; 100:451-471.
7. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009; 9:393-407.
8. 't Hart BA, Laman JD, Bauer J, et al. Modelling of multiple sclerosis: lessons learned in a nonhuman primate. Lancet Neurol 2004; 3:588-597. (Pubitemid 39232075)
9. Genain CP, Hauser SL. Experimental allergic encephalomyelitis in the New World monkey Callithrix jacchus. Immunol Rev 2001; 183:159-172. (Pubitemid 34015446)
10. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004; 173:3916-3924. (Pubitemid 39280755)
11. Su SB, Silver PB, Grajewski RS, et al. Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. J Immunol 2005; 175:6303-6310. (Pubitemid 41598869)
12. Bruckener KE, el Baya A,Galla HJ, Schmidt MA. Permeabilization in a cerebral endothelial barrier model by pertussis toxin involves the PKC effector pathway and is abolished by elevated levels of cAMP. J Cell Sci 2003; 116:1837-1846. (Pubitemid 36582170)
13. Goverman J, Woods A, Larson L, et al. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993; 72:551-560. (Pubitemid 23077743)
14. Lyons JA, Ramsbottom MJ, Cross AH. Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein. Eur J Immunol 2002; 32:1905-1913. (Pubitemid 34814546)
15. Sasaki M, Lankford KL, Brown RJ, et al. Focal experimental autoimmune encephalomyelitis in the Lewis rat induced by immunization with myelin oligodendrocyte glycoprotein and intraspinal injection of vascular endothelial growth factor. Glia 2010; 58:1523-1531.
16. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 2009; 31:497-511.
17. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999; 24:511-514.
18. Van Zwam M, Huizinga R, Heijmans N, et al. Surgical excision of CNS-draining lymph nodes reduces relapse severity in chronic-relapsing experimental autoimmune encephalomyelitis. J Pathol 2009; 217:543-551.
19. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2008; 10:55-66. (Pubitemid 351176056)
20. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106-2112. (Pubitemid 39626806)
21. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic antiaquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009; 66:617-629.
22. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66:630-643.
23. Ben-Nun A, Wekerle H, Cohen IR. The rapid isolation of clonable antigenspecific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981; 11:195-199. (Pubitemid 11104096)
24. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356:63-66.
25. Cannella B, Cross AH, Raine CS. Antiadhesion molecule therapy in experimental autoimmune encephalomyelitis. J Neuroimmunol 1993; 46:43-55.
26. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676-688. (Pubitemid 351240747)
27. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63:395-400. (Pubitemid 351499869)
28. Meinl E, Krumbholz M, Derfuss T, et al. Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J Neurol Sci 2008; 274:42-44.
29. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B-and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010; 67:707-714.
30. Matsushita T, Yanaba K, Bouaziz JD, et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118:3420-3430.
31. Weber MS, Prod'homme T, Patarroyo JC, et al. B-cell activation influences Tcell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010; 68:369-383.
32. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/ T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13:139-145.
33. Raine CS, The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 1994; 36 (Suppl):S61-S72. (Pubitemid 24220845)
34. Ruddle NH, Bergman CM, McGrath KM, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990; 172:1193-1200. (Pubitemid 20343220)
35. Selmaj K, Raine CS, Cross AH. Antitumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991; 30:694-700.
36. Codarri L, Fontana A, Becher B. Cytokine networks in multiple sclerosis: lost in translation. Curr Opin Neurol 2010; 23:205-211.
37. Huntington ND, Tomioka R, Clavarino C, et al. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol 2006; 18:1473-1485. (Pubitemid 44446825)
38. Stohlman SA, Hinton DR. Viral induced demyelination. Brain Pathol 2001; 11:92-106.
39. Lipton HL, Canto CD. Contrasting effects of immunosuppression on Theiler's virus infection in mice. Infect Immun 1977; 15:903-909. (Pubitemid 8077441)
40. McGavern DB, Murray PD, Rivera-Quinones C, et al. Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. Brain 2000; 123 (Pt 3):519-531. (Pubitemid 30099537)
41. Trottier M, Schlitt BP, Kung AY, Lipton HL. Transition from acute to persistent Theiler's virus infection requires active viral replication that drives proinflammatory cytokine expression and chronic demyelinating disease. J Virol 2004; 78:12480-12488. (Pubitemid 39458766)
42. Pachner AR, Brady J, Narayan K. Antibody-secreting cells in the central nervous system in an animal model of MS: phenotype, association with disability, and in vitro production of antibody. J Neuroimmunol 2007; 190:112-120. (Pubitemid 47625618)
43. Pachner AR, Li L, Narayan K. Intrathecal antibody production in an animal model of multiple sclerosis. J Neuroimmunol 2007; 185:57-63. (Pubitemid 46497441)
44. Dal Canto MC, Lipton HL. Primary demyelination in Theiler's virus infection. An ultrastructural study. Lab Invest 1975; 33:626-637.
45. Pachner AR, Li L, Lagunoff D. Plasma cells in the central nervous system in the Theiler's virus model of multiple sclerosis. J Neuroimmunol 2011; 232:35-40.
46. Lipton HL, Kumar AS, Trottier M. Theiler's virus persistence in the central nervous system of mice is associated with continuous viral replication and a difference in outcome of infection of infiltrating macrophages versus oligodendrocytes. Virus Res 2005; 111:214-223. (Pubitemid 40909737)
47. Vandevelde M, Zurbriggen A. Demyelination in canine distemper virus infection: a review. Acta Neuropathol 2005; 109:56-68. (Pubitemid 40287790)
48. Sips GJ, Chesik D, Glazenburg L, et al. Involvement of morbilliviruses in the pathogenesis of demyelinating disease. Rev Med Virol 2007; 17:223-244. (Pubitemid 47066636)
49. Waksman BH. Demyelinating disease: evolution of a paradigm. Neurochem Res 1999; 24:491-495. (Pubitemid 29187400)
50. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343:1430-1438.
51. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 2010; 133:1914-1929.
52. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55:458-468. (Pubitemid 38391962)
53. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53:457-465.
54. Meinl E, Derfuss T, Krumbholz M, et al. Humoral autoimmunity in multiple sclerosis. J Neurol Sci 2010 [Epub ahead of print].
55. Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev Neurother 2009; 9:319-321.
56. Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 2005; 58:939-945. (Pubitemid 41746884)
57. Friese MA, Montalban X, Willcox N, et al. The value of animal models for drug development in multiple sclerosis. Brain 2006; 129:1940-1952. (Pubitemid 44289061)
58. Mix E, Meyer-Rienecker H, Hartung HP, Zettl UK. Animal models of multiple sclerosis: potentials and limitations. Prog Neurobiol 2010; 92:386-404.
59. Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009; 40:2244-2250.
60. Crossley NA, Sena E, Goehler J, et al. Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke 2008; 39:929-934. (Pubitemid 351619572)
61. O'Collins VE, Macleod MR, Donnan GA, et al. 1026. experimental treatments in acute stroke. Ann Neurol 2006; 59:467-477.